Market research
HDP1.F Arrowhead Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 10B
- P/E ratio
- Not available
- Analyst target
- 87.92
- Dividend yield
- Not available
- Beta
- 1.29
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US04280A1007
- Market cap
- 10B
- P/E ratio
- Not available
- Analyst target
- 87.92
- Dividend yield
- Not available
- Beta
- 1.29
About
About Arrowhead Pharmaceuticals, Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HDP1.F discussion.
5 years, 5 months ago
Arrowhead Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 10.3% below its 200 day moving average.
From a valuation standpoint, the stock is 93.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 84.2.
Arrowhead Pharmaceuticals, Inc's total revenue sank by 27.7% to $21M since the same quarter in the previous year.
Its net income has dropped by 675.4% to $-21M since the same quarter in the previous year.
Finally, its free cash flow fell by 55.1% to $-43M since the same quarter in the previous year.
Based on the above factors, Arrowhead Pharmaceuticals, Inc gets an overall score of 1/5.